For patients with pancreatic cancer, the benefits from immunotherapy treatments with immune checkpoint inhibitors or cell therapies have been limited so far. This is partly because pancreatic cancers create an environment that blocks an effective immune response. Also, these tumors have few neoantigens, or mutant proteins, which normally allow the immune system to recognize them as unhealthy cells.
But MD Anderson researchers have...
Last updated on November 6, 2023
Immunotherapy is a treatment option for a growing number of cancers. Unlike traditional treatments...
Minimal residual disease (MRD) is a term commonly used with blood cancers that describes a small fraction of cancer cells that remain or come...